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1. Introduction 
Cancer, a leading cause of death globally, is projected to become more prevalent in coming 
years due to increasing life expectancy. Among possible treatment options, the use of 
biomarkers especially has shown great potential as a gateway to personalized medicine, and 
in turn, great promise for improved diagnosis, prognosis and treatment of cancer and other 
diseases. However, the use of biomarkers in cancer therapeutics has thus far exhibited mild 
success, at best. The most common tool used for biomarker discovery is plasma proteomics 
due to the accessibility of blood samples and the rapid development of highly sensitive 
proteomics technologies. However, other body fluids such as urine may also be a reservoir 
for important marker proteins. 
Extracellular membrane vesicles ranging in diameter of 30-1000 nm and originating from 
various cellular origins have been increasingly recognized for their participation in a variety 
of both normal and pathological cellular processes. Regardless of their cell type of origin 
these membrane bound vesicles or exosomes provide a protected and controlled internal 
microenvironment outside the cell for metabolic objectives of the host cell to be carried out 
at a distance from the host cell. They are also believed to be instrumental in cell-cell and cell-
extracellular communication. Moreover, while knowledge of exosome biogenesis and 
physiological relevance remains limited, accumulating evidence suggests that their 
bioactivity may be clinically applicable in cancer therapeutics. One recent work suggests 
that the use of exosomes in immunotherapy may prime the immune system to recognize 
and kill cancer cells and thus could form a viable basis for the development of novel cancer 
vaccines.  
This chapter will review current knowledge pertaining to exosomes, describe possible uses 
of exosomes in immunotherapy, and address challenges and future directions in bringing 
exosome-based cancer vaccines or immunotherapies closer to clinical reality. 
2. Exosome biogenesis, secretion and physiologic considerations 
Since their description in the process of reticulocyte maturation almost a quarter century ago 
(Johnstone et al., 1987), exosomes; the intralumenal vesicles (ILV’s) of multivesicular bodies 
(MVB’s), have gained significant notoriety as evidenced by the nearly 10-15 fold rise in the 
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amount of publications devoted to the subject just within the past decade (Raimondo et al., 
2011). 
Many types of vesicles have been described in the literature having quite heterogeneous 
size, protein content, RNA content and origin. As a result there have been many names 
given to these different vesicle types (Table 1) (Ronquist & Brody, 1985; Ronquist & Frithz, 
1986; Rooney et al., 1993; Arienti et al., 1997; Thery et al., 2006; Lehmann et al., 2008; Schiller et 
al., 2008; Simpson et al., 2008; Skog et al., 2008; Dashevsky et al., 2009; Di Vizio et al., 2009; 
Haubold et al., 2009; Jansen et al., 2009; Nilsson et al., 2009; Duijvesz et al., 2010). 
Unfortunately, the different names given to these vesicles lead to much confusion and it is 
still unclear if all of the different vesicles are unique in biological function or if they 
represent a sliding scale of one entity (Duijvesz et al., 2010). Exosomes are nanometer sized 
lipid bound vesicles derived from late endosomes contained in MVB’s. They are 
characterized by their size 40-100nm, density ranging from 1.13g/ml to 1.19g/ml on a 
sucrose gradient (Record et al., 2011) and their specific protein content (heat shock proteins, 
tetraspanins, Rab proteins, etc) Figure 1. Exosomes are secreted by both hematopoietic (eg 
dendritic cells, lymphocytes, mast cells) and non-hematopoietic cells such as fibroblasts, 
intestinal epithelium, neurons and various tumor cells. Exosomes have been isolated from 
serum and other biological fluids such as urine, ascitic fluid, amniotic fluid and even 
cerebrospinal fluid (Vella et al., 2008). Exosome biogenesis involves an inward budding of 
the limiting membrane of late endosomes, also known as multivesicular bodies (MVBs) 
(Figure 2), concurrent protein sorting into these budding exosomes, and subsequent 
splitting (scission) of these microvesicles (Keller et al., 2006). As a consequence, the nascent 
exosome contains the inner leaflet of the limiting membrane, membrane associated proteins, 
both native and recruited, and some amount of cytosol and cytosolic proteins.  
 
 
Table 1. Characteristics of different types of microvessicles. 
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Fig. 1. Tumor derived exosomes (TEX). A. Electron microscopy revealed 50-100 nm sized 
microvesicles (Khan et al., 2011). B. Diagram depicting a typical TEX (modified from JP 
Mitchel, exosomes in cancer immunology). 
The presence of specific proteins within and on the vesicle suggest the existence of a protein 
sorting mechanism during its formation. Some of these proteins are shared by exosomes 
derived from different sources and used to identify these vesicles during proteomic analysis. 
In our laboratory, we have consistently used the lysosomal associated membrane protein 
LAMP1 (common to exosomes from a wide variety of cells) as a positive control for exosome 
presence in western blot analysis (Khan et al., 2011). 
 
 
Fig. 2. Protein loading and release by exosomes. Endocytosed surface proteins as well as a 
subset of cytosolic proteins are taken by the endosomal system. Those destined for release as 
exosomes or for lysosomal degradation are sorted into lumenal vesicles called 
multivesicular bodies (MVB). 
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2.1 ESCRT-dependent protein sorting 
The specific protein content of exosomes can be exploited to identify these exosomes and the 
cell-types from which they are derived via proteomic analysis. The fact that the exosome’s 
protein content can be used as an identifier suggests the existence of a protein sorting 
mechanism during its formation. Endosomal Sorting Complex Required for Transport 
(ESCRT), comprised of a series of three protein complexes: ESCRT I, ESCRT II, and ESCRT 
III (Figure 3), is suspected to play a critical role in sorting proteins into exosomes at the 
endosomal limiting membrane. 
 
 
Fig. 3. Ubiquitin marks cargo proteins for endosomal sorting. 
Monoubiquitination appears to mark cargo proteins for protein sorting within the MVBs. In 
yeast, recruitment of ubiquitinated cargo proteins depends on a class of proteins known as 
class E Vps (Vacuolar Protein Sorting) proteins that have been highly conserved from yeast 
to mammals—at least one mammalian homolog has been identified for each yeast class 
member (Babst, 2005). In the yeast model, Vps 27, is thought to complex on the endosomal 
membrane’s outer leaflet with clathrin and ubiquitin-binding proteins, such as Golgi-
associated, ┛-adaptin homologs, Arf-binding (GGA) proteins, to form an endosomal clathrin 
coat that recruits monoubiquitinated cargo to the inner leaflet of the endosomal membrane. 
This complex recruits the ESCRT I complex from the cytoplasm and transfers to it the 
ubiquitinated cargo. ESCRT I then activates ESCRT II, which in turn occasions the 
oligomerization of Vps 2, Vps 20, Vps 24, and Snf 7 to form the ESCRT III complex and 
transfers to ESCRT III the ubiquitinated cargo. ESCRT III continues to accumulate and 
concentrates the cargo into still-budding exosomes of the MVB (Babst, 2005). The 
deubiquitinating protein Doa4 is then recruited into the complex where it functions to 
remove the ubiquitin from the cargo protein (Luhtala & Odorizzi, 2004). The ESCRT III 
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complex subsequently dissociates from the cargo when the ATPase Vps 4 binds, thus 
releasing the cargo protein into the budding exosome. 
2.2 Other modes of protein sorting 
Other exosomal proteins, for which no ESCRT mechanisms have been described, may be 
incorporated into the exosome via varying levels of co-sorting. For example, tetraspanins may 
sort into exosomes due to their affinity for exosomal membrane components like sphingolipids 
and ceramides and may follow these phospholipids to further aggregate into lipid raft 
domains (de Gassart et al., 2003). Protein-protein associations also contribute to co-sorting. 
MHC Class II molecules can associate with tetraspanins and be co-sorted into exosomal 
membranes (Blanc & Vidal, 2010). Some evidence also suggests lipid co-sorting into exosomes. 
The exosomal lipid LBPA (Lysobisphosphatidic Acid) can sort into exosomal membranes by 
interaction with the exosomal protein Alix. When present in media, LBPA was also shown to 
assist with the formation of vesicles in the MVBs (Matsuo et al., 2004). 
Hematopoietic cells including dendritic cells, lymphocytes and mast cells, and non-
hematopoietic cells such as fibroblasts, intestinal epithelial cells, neurons and various tumor 
cells secrete exosomes. Exosome release from cells may follow a constitutive versus an 
inducible mode of secretion. The constitutive pathway utilizes the trans-golgi network, after 
which the vesicles travel through the cytoplasm via an intricate tubular network and 
eventually are released into the extracellular space (Ponnambalam & Baldwin, 2003). The 
inducible mode involves the release of preformed vesicles contained in MVBs. Such release 
may be dependent on known cellular triggers of vesicle release, such as increased intracellular 
calcium levels (Savina et al., 2003). Other triggers, such as cellular depolarization, have also 
been described. These events culminate in the fusion of MVB membrane with the cell 
membrane and subsequent exosome release into the extracellular space. 
Exosomes interact with target cells via specific receptors present on these target cells 
(Losche et al., 2004). The exosome thus exerts its effect either via receptor-receptor 
interaction or internalization of the exosome with subsequent interaction of the exosome 
content with the recipient cellular machinery (Record et al., 2011). 
As will be described in other sections of this chapter, exosomes influence immune cells both 
in normal and abnormal states such as cancer. Furthermore RNA contained in exosomes 
could be translated within the recipient cell and as a result exert an epigenetic influence (Baj-
Krzyworzeka et al., 2006). In this regard, exosomes mimic viral particles by directing host 
cellular processes to its advantage. The role of exosomes in inflammatory conditions has 
recently been questioned after platelets and macrophage derived microparticles/exosomes 
were found in the lipid core of artherosclerotic plaques (Leroyer et al., 2008). It is of interest 
to better understand the precise pro-inflammatory and thrombotic roles of exosomes and 
potentially use them as therapeutic targets in these conditions. Finally, the discovery of 
exosomes in urine has opened up the possibility of exosomal proteins being used as 
biomarkers for disease. It was recently shown that decreased levels of exosomal aquaporin-1 
correlates with renal ischemia-reperfusion injury (Sonoda et al., 2009). What makes this 
prospect exciting is the relative abundance of urine that can be obtained without an invasive 
procedure. 
2.3 Summary 
Exosomes are small membrane bound vesicles of endocytic origin that are released by most 
cells. The purpose for release seemed at first to be to discard membrane proteins and those 
www.intechopen.com
 Advances in Cancer Therapy 
 
26
believed to be resistant to lysosomal degradation. Now, it is believed that they mediate 
intercellular communication without the need for direct cell-to-cell interaction. 
3. Existence of secreted membrane vesicles in cancers 
Tumors are known to shed membrane vesicles (Taylor & Gercel-Taylor, 2005). In particular, 
human and mouse tumor cells have been shown to secrete tumor cell-derived exosomes 
(TEX), constitutively into the extracellular space (Wolfers et al., 2001). The morphology, 
density and certain membrane markers expressed, such as LAMP1, MHC class I, HSP70 and 
HSP80, on the released TEX are similar to the dendritic cell-derived exosomes (DEX) (Andre 
et al., 2002b) which will be discussed later. Despite similarities to DEX, there are differences 
in the molecular profiles and biological roles of TEXs, both of which give an indication of 
the cell of origin (Wieckowski & Whiteside, 2006). The specific protein content found on and 
within exosomes not only reflects their origin, but in addition, establishes their functional 
role (Zitvogel et al., 1998) (Table 2). TEX secreted from neoplastic cells express diverse 
tumor antigens, which signifies the type of tumor cells from where TEXs were released (Iero 
et al., 2008). In-vitro, it has been shown that TEX released from breast carcinoma cells contain 
HER2, while carcinoembryonic antigen (CEA) was found in the exosomes secreted from 
colon carcinoma cells, and proteins MelanA/Mart-1 and gp100 that are expressed in 
melanoma cells are found on the released TEX (Andre et al., 2002b; Andreola et al., 2002). 
This phenomenon is also evident in-vivo, where plasma from cancer patients contain 
membrane vesicles that are characterized by the expression of tumor antigens which reflect 
the tumor of origin (Hegmans et al., 2004; Mears et al., 2004). 
When immunocompetent and nude mice were pre-treated with murine mammary TEX, an 
accelerated growth of the tumor was observed (Liu et al., 2006). This observation led to various 
studies to try to elucidate the role of secreted membrane vesicles in cancer. TEX can be 
described as “multi-purpose carriers” which have important roles in the communication, 
protection, as well as the exchange of genetic information with neighboring cells (Nieuwland 
& Sturk, 2010). The production and secretion of TEX is important for the tumor. They serve a 
protective function, have a supportive role in the survival and growth of the tumor cells, are 
involved in the promotion of host tissue invasion and subsequent metastasis, and facilitate 
evasion from the immune response (Valenti et al., 2007; Anderson et al., 2010). Acting in a 
paracrine fashion, the diverse function of TEX is speculated to be due to the various bioactive 
molecules found within and on the vesicles having a strong influence on the surrounding 
environment (Hegmans et al., 2004; Mears et al., 2004; van Niel et al., 2006; Iero et al., 2008). 
The promotion of angiogenesis is due in part to the upregulation of vascular endothelial 
growth factor (VEGF) (Skog et al., 2008) and release of matrix metalloproteinases (MMPs) in 
neighboring, even distant endothelial cells, which are brought by TEX containing 
tetraspanin family members (Gesierich et al., 2006), epithelial growth factor receptor (EGFR) 
(Al-Nedawi et al., 2009), platelet-derived tissue factor (TF) (Osterud, 2003) or developmental 
endothelial locus-1 protein (Hegmans et al., 2004). TEX has also been implicated in the 
further growth of tumor by the exchange of genetic material. mRNA was detected within 
exosomes released from glioblastoma cells. Neighboring microvascular endothelial cells that 
take up the exosomes and translate the mRNA become liable for further tumor growth 
leading to the stimulation of angiogenesis (Skog et al., 2008). In addition, tissue invasion and 
stromal remodeling can be facilitated by proteases and MMP transport and release via 
exosomes (Ginestra et al., 1998; Graves et al., 2004).  
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Cancer Type Protein References 
 
Breast adenocarcinoma
(BT-474 
MDA-MB-231, TS/A, H-2,
P815) 
ERBB2*/HER2* (Andre et al., 2002b; 
Koga et al., 2005) 
Cervical Cancer (heLa) Survivin, HSP 70, HSP 90 (Khan et al., 2011) 
Colorectal Cancer 
(LIM1215, HT29, SW403, 
1869COL, AND CRC28462, 
LIM1215) 
 
GPA 33*, CEACAM5*, EFNB1*
annexins, ARFs*, Rabs*, ADAM10*,
CD44*, NG2 ephrin-B1, MIF*, b-
catenin, junction plakoglobin
galectin-4, RACK1*, and tetraspanin-
8, FASL* AND TRAIL* FASLG*
TNFSF10* 
(Andreola et al., 2002; 
Abusamra et al., 2005b; 
Huber et al., 2005; Taylor 
& Gercel-Taylor, 2005; 
Choi et al., 2007; 
Simpson et al., 2009) 
Glioma Cancer 
 
EGFR* (Al-Nedawi et al., 2009) 
Melanoma  
(Fon and Mel-888) 
 
TRP*GP100*MART-1* 
Mel-CAM*FASLG*TNFSF10* 
A33*, CEA, EGFR*, ADAM10*, 
dipeptidase 1 ephrin-B1, hsc70, 
tetraspanins, ESCRT proteins
(integrins, annexins, Rabs, and
GTPases) 
(Andre et al., 2002b; 
Mears et al., 2004; 
Abusamra et al., 2005b) 
Mesothelioma PLVAP* (Hegmans et al., 2004) 
Ovarian 
 
ERBB2* (Andre et al., 2002b; 
Andreola et al., 2002; 
Koga et al., 2005) 
Prostate  
 
FASLG* 
TNFSF10* 
(Huber et al., 2005; Kim 
et al., 2005) 
Squamous cell cancer FASLG 
TNFSF10 
(Taylor et al., 2006; 
Martinez-Lostao et al., 
2010) 
Table 2. Protein content on and within exosomes reflects their origin and establishes their 
functional role. Cell surface A33 antigen precursor (GPA 33); Carcinoembryonic antigen-
related cell Adhesion molecule 5 (CEACAM5); Ephrin-B1 (EFNB1); ADP-ribolysing factor 
(ARF), Ras-Gprotein superfamily (Rabs), A disintegrin and metaloprotease (ADAM10), 
Macrophage Migration inhibitory factor (MIF), Receptor for activated C-kinase (RACK1), 
5,6-Dihydroxyyindole-2 carboxylic acid oxidase (TRP); Epidermal-growth factor receptor 
(EGFR); Receptor tyrosine-protein kinase erbB-2 (ERBB2); Plasmalemma vesicle associated 
protein (PLVAP); Melanocyte Protein Pmel 17 (GP100); Melanoma Antigen Recognized by T 
cells 1 (MART-1), Mel-CAM, TNF-ligand superfamily member 10 (TRAIL) TNF-ligand 
superfamily member 6 (FasL). 
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Recent studies have shown that TEX provide a protective role to the cancer cells, which can 
be manifested in different ways. Survivin, a member of the inhibitor of apoptosis (IAP) 
protein family, was found to be released from tumor cells via exosomes (Khan et al., 2011). 
The protective role of TEX can be attained by the accumulation and packaging of 
chemotherapeutic drugs or its metabolites into the vesicles, thus decreasing cellular levels of 
the drug, a factor leading to drug resistance (Shedden et al., 2003; Safaei et al., 2005). This 
phenomenon has been observed in various cancer cells. Cisplatin enhanced the shedding of 
the vesicle from melanoma cells (Chen et al., 2006a), while doxorubicin was found in the 
exosomes released from ovarian carcinoma cells (Shedden et al., 2003). 
Despite the beneficial roles of TEX for the tumor cells and the tumor microenvironment, 
TEX can be a useful tool for detecting the malignant condition. Serum levels of exosomes 
taken from cancer patients are significantly increased. These vesicles taken from serum 
(Ginestra et al., 1999), as well as from malignant tumor fluids, such as ascites fluids (Adams 
et al., 2005), pleural effusions (Andre et al., 2002b) and urine (Nilsson et al., 2009), positively 
correlate with the tumor progression.  
3.1 Constitutive and inducible vesicle secretion in cancer and cancer therapy 
In the tumor microenvironment, various changes are taking place, which could have an effect 
on the release of vesicles, such as exosomes. Environmental changes, such as stress induced by 
chemo- and radio-therapy, can modulate TEX release and the biome they contain. This 
phenomenon may induce the tissues to adapt to changes taking place in the microenvironment 
(Thery et al., 2009). Tumor cells that have undergone radiation or chemotherapy treatment 
have been shown to increase the release of TEX (Yu et al., 2006; Lehmann et al., 2008). 
Interestingly, when treated with chemotherapeutic agents, there is a significantly enhanced 
membrane vesicle secretion in chemoresistant cells compared to chemosensitive cells. This 
activity may be a factor leading to drug resistance (Shedden et al., 2003; Safaei et al., 2005). 
Chemotherapy and radiation (Chen et al., 2006b) treatment lead to DNA-damaging 
conditions. In this state, the p53 pathway is activated, leading, among various other changes 
physiologically, to an induced expression of the transmembrane protein tumor suppressor-
activated pathway 6 (TSAP6). TSAP6 is an important cellular component as it regulates the 
secretion of protein via the non-classical pathway or the ER/Golgi-independent protein 
secretion pathway needed for the enhanced release of exosomes (Nickel, 2003; Yu et al., 2006; 
Lespagnol et al., 2008). Normally, the secretion of exosomes in various cell types happens at 
a low rate. However, when p53 is activated, endosomal compartment activities are 
activated. Simultaneously, there is an increased expression of TSAP6, inducing the release of 
exosomes at a higher rate (Yu et al., 2009) (Figure 4). It is suggested that following p53 
activation, exosomal release may act as a ‘detoxifier’ to expel unwanted chemotherapeutic 
agents (Shedden et al., 2003; Safaei et al., 2005; Chen et al., 2006b; Lespagnol et al., 2008). 
Communication to the microenvironment is the other proposed role of TSAP6 and exosomal 
release after p53 activation, which may act as a warning signal to the neighboring cells, the 
immune system, and the extracellular matrix, that there are abnormal intracellular events 
happening (Lespagnol et al., 2008; Yu et al., 2009). 
3.2 Summary 
TEX can be used as an important biomarker for the disease, which will give information not 
only on the disease progression, but on the tumor type. As previously mentioned, TEX 
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express specific tumor antigens which reflect the protein content of the tumor, giving an 
indication of the tumor type. The content of these vesicles can also be useful as markers for 
the aggressiveness of the disease. 
 
 
Fig. 4. Activation of p53 by DNA damage induces the expression of TSAP6 which enhances 
exosome-mediated secretion. 
4. Proteome of cancer membrane vesicles 
Mass spectrometry-based proteomic tools coupled with advanced purification methods for 
exosomes, has allowed more in-depth proteome analyses, contributing immensely to our 
understanding of the molecular composition of exosomes. Proteomic analysis of exosomes 
from diverse cell types, including cancers has revealed a common set of membrane and 
cytosolic proteins, suggesting the evolutionary importance of these membrane particles. In 
addition, exosomes express an array of proteins that reflect the originating host cell. The 
excessive release of exosomes in tumor cells, as evidenced by their increased levels in body 
fluids during the late stage of a disease and their overexpression of certain tumor cell 
biomarkers, suggests an important role of exosomes in diagnosis and biomarker studies 
(Simpson et al., 2009). 
By proteomic analysis we can enrich low abundance membrane proteins from 
underrepresented conventional cell lysates and unfractionated biological fluids. 
Identification of a conserved set of common proteins that are essential for vesicle biogenesis, 
structure and trafficking mechanisms can be explored. We can also detect cell-specific 
biomarkers. These concepts suggest that analyzing the composition and abundance of such 
proteins in exosomes may be useful to reveal different cell behaviors. 
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4.1 Proteomics of cell-type dependent exosomes 
Exosomes have a unique protein composition that varies depending on cellular origin 
(Table 2). Analysis of exosomes from a wide variety of cells and body fluids have been 
identified. Exosomes from various cancer cells expose Fas ligand (FasL, CD95L), a ligand of 
the death receptor Fas (CD95), which induces T-cell apoptosis and diminishes the function 
of adaptive immune cells (Andreola et al., 2002; Huber et al., 2005). It was shown that a 
modest correlation exists between lymph node infiltration and tumor burden and the 
numbers of circulating FasL-exposing exosomes in blood from patients with oral squamous 
cell cancers (Kim et al., 2005). Exosomes from lymphoblastoma cells exposed latent 
membrane protein-1 (LMP-1), another immune suppressing transmembrane protein, 
thereby inhibiting leukocyte proliferation. In addition, low numbers of circulating 
exosomes, in cancer patients, stained positive for MUC1, a cancer cell antigen, and 
glycoprotein IIIa (integrin ┚3), which is mainly present on platelets and platelet-derived 
exosomes. Exosomes are released after fusion of exosomes from malignant epithelial cells 
with platelets (Tesselaar et al., 2007). Alternatively, platelet-derived exosomes were shown 
to transfer integrins to breast and lung cancer cells (Janowska-Wieczorek et al., 2001; 
Janowska-Wieczorek et al., 2005). Thus, cancer cells can fuse with non-cancer cell-derived 
exosomes, thereby receiving lipids and membrane specific proteins which may help them 
escape from immune surveillance. 
Degradation of the extracellular matrix (ECM) is essential for tumor growth (Hotary et al., 
2003). Exosomes expose and contain proteases, including matrix metalloproteinase 2 (MMP-
2) and MMP-9 and its zymogens, and urokinase-type plasminogen activator (uPA). 
Neovascularization is also responsible for the increased entry of tumor cells into the 
circulation and metastasis. It is believed that tumor and stromal cells secrete angiogenic 
factors such as VEGF and basic fibroblast growth factor (bFGF) and that tumor-associated 
angiogenesis occurs by the action of these factors (Carmeliet, 2005). Furthermore, growing 
evidence suggests that exosomes derived from tumor cells and platelets also possess 
angiogenic activities. Vesicular components such as sphingomyelin, CD147, tetraspanin-8, 
VEGF, and bFGF are likely involved in exosome-mediated neovascularization (Kim et al., 
2002; Brill et al., 2004; Gesierich et al., 2006; Millimaggi et al., 2007). 
In a colorectal cancer cell line study, several exosomal proteins have been identified that are 
believed to be involved in tumor-associated angiogenesis: ADAM 10, CD44, NG2, ephrin-
B1, macrophage migration inhibitory factor (MIF), RACK1, and tetraspanin-8 (Dong-Sic et 
al., 2007). Clinical exosome analysis may also prove useful for solid cancers (Mathivanan et 
al., 2010). Using exosomes from ovarian carcinoma cell lines, malignant ascites and sera 
from ovarian carcinoma patients, it was found that malignant ascites-derived exosomes 
cargo tumor progression related proteins (L1CAM, CD24, ADAM10 and EMMPRIN). It was 
also observed that exosomes move systemically via the blood stream (Keller et al., 2009). 
Therefore, if some membrane proteins are typically and specifically expressed by a certain 
tumor, their detection on circulating exosomes, (which could be isolated from only 1mL of 
blood), may be exploited for diagnostic purposes as an early signal of cancer presence. 
Proteomic analysis of exosomes was also performed on human mesothelioma cell lines and 
malignant pleural effusions. Bard and colleagues, described exosomes which contained 
antigen presenting molecules, cytoskeletal proteins, and signal tranduction-involved 
proteins were in mesothelioma, lung, breast, and ovarian cancers. In addition, SNx25, BTG1, 
PEDF, and Thrombospondin were also identified (Bard et al., 2004). 
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Characterization of urinary exosomal composition may be proposed as a potential source of 
diagnostic markers in bladder cancer. Two different approaches (Smalley et al., 2008; Welton 
et al., 2010) were taken to characterize these exosomes. In the first, urine exosomes were 
isolated from a limited number of individuals with bladder cancer and their protein 
composition compared to that of healthy controls. Eight proteins were found elevated, 
among which five have been linked to the EGF receptor pathway (Smalley et al., 2008). In the 
second study, extensive steps were taken to produce high purity and quality-assured 
exosome preparations prior to beginning proteomics workflows. Working with conditioned 
media from cultured bladder cancer cell lines, 350 proteins were identified. Eighteen were 
proven to be present in exosomes isolated from the urine of three bladder cancer patients 
(Welton et al., 2010). This suggests that conditioned media from cultured cell lines could 
represent an interesting starting model to detect exosomal proteomic alterations, which 
must then be confirmed in vivo, using biological fluids from a wide cohort of patients, in 
order to supply a non-invasive source for biomarker discovery. 
Exosomes prepared from urine of prostate cancer patients contain typical markers of such a 
tumor (PSA and PCA3) (Mitchell et al., 2009; Nilsson et al., 2009). Moreover, -catenin 
immunoreactivity was identified in vesicles prepared from culture media of PC3 cells and 
found significantly increased in prostasomes of the urine of prostate cancer patients (Lu et 
al., 2009).  
4.2 Summary 
Studies confirm that urinary exosome protein profiling is an important topic and may be a 
valuable tool for biomarker discovery in the field of urinary tract pathology. Proteomic 
approaches to investigate membranous vesicles and exosomes are still immature. However, 
they show a great potential for future developments in the diagnostic and prognostic 
applications. 
5. Targeting interactions of membrane vesicles with neighboring tumor 
microenvironment 
Tumor cells release large quantities of exosomes containing procoagulant, growth 
regulatory, and oncogenic cargo, which can be transferred throughout the cancer cell 
population and to transformed stromal cells, endothelial cells and possibly to the 
inflammatory infiltrates. These events likely impact tumor invasion, angiogenesis, 
metastasis, drug resistance, and cancer stem cells. Instead of physical contact, the influence 
of exosomes on the target cell may also involve pericellular discharge/activation of the 
bioactive cargo (Dolo et al., 2005; Hendrix et al., 2010; Muralidharan-Chari et al., 2010). For 
instance, this may involve proteolytic remodelling of the extracellular microenvironment, 
modulation of ligand-receptor interactions, and a variety of other effects that could change 
the behaviour of target cells and properties of their surroundings (Hendrix et al., 2010) 
(Figure 5). In some instances, such interactions could be rather complex and multifactorial. 
The recently described Rab27B-regulated exosomal release of MMPs and HSP90a from 
metastatic cancer cells is believed to control invasive cellular behaviour by inducing changes 
in the extracellular matrix (ECM) as well as through modification of growth factor responses 
(Hendrix et al., 2010). Likewise, procoagulant exosomes may facilitate tumor initiation, 
invasion, and dissemination by activating the clotting cascade extracellularly and 
coagulation-dependent signalling intracellularly (Milsom et al., 2007). Exosome-mediated 
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emission of various factors including tetraspanins, chemoattractants, adhesion molecules 
and proteases from cancer cells, platelets, and other cellular sources contributes to 
metastatic regulation in several experimental systems (Janowska-Wieczorek et al., 2005; Jung 
et al., 2009). As mentioned earlier, exosomes may also act as important reservoirs of 
cytokines and mediators of inflammatory and immune responses (Bianco et al., 2009; Thery 
et al., 2009). 
5.1 Mediators of intercellular communication 
Contact with the cell death ligand (FasL) exposed on certain tumor cell-derived exosomes is 
lethal for Fas-expressing lymphoid cytotoxic effector cells, a process implicated in the 
induction of immunotolerance in colorectal cancer and possibly other malignancies 
(Albanese et al., 1998). These influences may affect recipient cells via a random distribution 
of exosomes in tissue and body fluids, or more directional exosome homing/uptake 
mechanisms. For instance, an acidic pH commonly present in hypo-perfused areas of solid 
tumors may lead to localized disruption of exosomes and consequent discharge of their 
proangiogenic and pro-inflammatory cargo such as VEGF and other factors (Taraboletti et 
al., 2006). Exosomes may also be directed to specific sites due to the molecular addresses 
they carry on their surfaces (Celi et al., 2004; Zhou et al., 2008; Xiao et al., 2009). The nature, 
directionality, and efficiency of this molecular exchange depends on several factors. For 
instance, the physical properties of vesicular plasma membranes affect the fusion rate 
between exosomes and target cells, which may increase their exosome uptake under acidic 
pH (Parolini et al., 2009). In some instances, exosome transfer could also be directed by 
specific molecular addresses, for example, a high concentration of phosphatydyl serines (PS) 
on the surface of certain exosomes (e.g. ectosomes or procoagulant microparticles) may 
enable their recognition by PS receptors (PSRs) on the surface of specific types of target cells. 
Many of such PSRs have been described within the context of phagocytosis of apoptotic cells 
by mononuclear cells; examples of such PSRs include Tim1, Tim4, stabilin 2 and BAI1 (Park 
et al., 2007; Zhao et al., 2010), at least some of which could be expressed more widely and 
may be involved in the uptake of exosomes. Indeed, blocking PSRs often obliterates 
exosome incorporation by endothelial cells, platelets and cancer cells (Del Conde et al., 2005; 
Al-Nedawi et al., 2008; Al-Nedawi et al., 2009). A corollary to this point would be that 
phagocytes could be particularly susceptible to molecular influences of PS-positive 
exosomes, beyond their simple destruction. It has also been proposed that Tim1/4 receptors 
on two adjacent cells could allow formation of exosome bridges, thereby promoting 
additional indirect intercellular interactions (Xiao et al., 2009). Similarly, the presence of 
PSGL-1 (P-selectin ligand) on the surface of procoagulant exosomes directs them to P-
selectin-expressing platelets and endothelial cells (Thomas et al., 2009). 
5.2 Oncosomes: Oncogene-driven vesiculation 
During malignant transformation, the action of mutant oncogenes, such as K-ras, EGFR, or 
its constitutively active mutant EGFR (variant III) (EGFRvIII), as well as several others, 
appear to stimulate the formation and release of exosomes (Yu et al., 2005; Al-Nedawi et al., 
2008). Similarly, the activation or loss of specific tumor suppressor proteins appears to 
impact cellular vesiculation either positively or negatively (Yu et al., 2005; Yu et al., 2006). 
While the exact nature of the signalling pathways involved in oncogene-driven exosome 
biogenesis remains largely unknown, recent studies have begun to shed more light on the 
underlying processes. For instance, in cultures of prostate cancer cells, elevated exosome 
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production was detected in association with increased oncogenic activity of protein kinase B 
(PKB/Akt), or upon stimulation with growth factors (EGF), and depending on the status of 
the actin regulating protein known as diaphanous related formin 3 (DRF3) (Di Vizio et al., 
2009). In this case, inhibition of DRF3 expression through RNA interference enhanced the 
rate of exosome formation, and membrane blebbing activity, suggesting that DRF3 may be 
an inhibitor of ectosome release (Di Vizio et al., 2009). Interestingly, DRF3 expression is lost 
during the progression of prostate cancer to metastatic disease, which suggests an intriguing 
link between oncogenesis, vesiculation and metastasis (Di Vizio et al., 2009).  
 
 
Fig. 5. Tumor microenvironment. The heterotypic interactions within the tumor 
microenvironment and their give and take of exosomes and their contents provide many 
targets for possible therapy. The goal of targetting these interactions will interrupt the 
heterotypic signaling that would thus deprive the cancer cells of the support they have 
within the tumor microenvironment. 
5.3 Effect of TEX on tumor microenvironment 
Exosome release by colorectal cancer cells is a function of K-ras and p53 status (Yu et al., 2005). 
It is noteworthy that oncoproteins not only stimulate exosome formation but also become 
incorporated into their cargo (Al-Nedawi et al., 2008; Al-Nedawi et al., 2009). As a result, 
oncogene-containing exosomes (sometimes refered to as oncosomes) may serve as vehicles that 
carry oncogenic cargo and mediate its transfer between cells (Al-Nedawi et al., 2009). At least 
four different modes of such oncogenic transfer have been described: (a) intercellular passage 
of active oncoproteins (Al-Nedawi et al., 2008), (b) transfer of oncogenic mRNA transcripts 
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(Skog et al., 2008), (c) exchange of oncogenic miR and/or (d) passage of genomic sequences 
containing oncogenic DNA (Bergsmedh et al., 2001). In many instances, this horizontal transfer 
may have marked biological (transforming) consequences. Thus, oncosomes containing 
EGFRvIII may emanate from malignant tumor cells and be taken up by their indolent 
counterparts inducing their growth, survival, and clonogenic and angiogenic capacity (Al-
Nedawi et al., 2008). These exosomes may also act on endothelial cells and reprogram their 
responses such that they exhibit an increase in angiogenic activity (Skog et al., 2008) or switch 
to an autocrine mode of secretory pathway, e.g. by turning on VEGF production (Al-Nedawi et 
al., 2008). Indeed, blocking exosome uptake using the Annexin V analogue (Diannexin) is 
associated with a measurable anti-angiogenic effect in vivo (Al-Nedawi et al., 2008). In chronic 
lymphoblastic leukaemia (CLL), exosomes containing AXL kinase conditioned the bone 
marrow stroma to support disease progression (Ghosh et al., 2010). These and similar effects 
identify exosomes as possible effectors of oncogenic and proangiogenic field effects, long 
postulated to exist in cancer (Slaughter et al., 1953; Al-Nedawi et al., 2009) and viewed as a 
mechanism of cell recruitment to the malignant process. 
5.4 Intercellular exchange 
Interactions between exosomes and their target cells may depend on the specific ligand-
receptor recognition events. For instance, platelets take up procoagulant exosomes in a 
manner that depends on the expression of P-selectin and its ligand (PSGL-1) on the 
respective surfaces (Falati et al., 2003). After the uptake, exosome-associated material was 
shown to penetrate into the cytoplasm of the acceptor cell (Skog et al., 2008) or to remain on 
the cell surface, potentially in the immediately active form (Del Conde et al., 2005; Al-
Nedawi et al., 2008). Interestingly, cloaking PS by exposure of exosomes to Annexin V often 
obliterates their uptake by target cells. Recent studies suggested that exosomal transfer 
would encompass multiple effectors at once (Skog et al., 2008). Such exosomal exchange 
could contribute to tumor angiogenesis by mechanisms dependent on transfer of oncogenes 
(Rak, 2010) (e.g., EGFRvIII4 or mRNA), but possibly also through bidirectional trafficking of 
other molecules (e.g., VEGFRs, Tie, Notch), including ligands traditionally assumed to act 
almost exclusively in a cell-associated manner (Dll4, ephrins) (Kerbel, 2008). This prototype 
has been already validated in the case of exosomal emission of coagulation factors (e.g., 
tissue factor—TF21), chemokine receptors (Mack et al., 2000) adhesion molecules (Falati et 
al., 2003), immunomodulators (Valenti et al., 2007), cell surface antigens (Dolo et al., 2005), 
intact RNA species (Ratajczak et al., 2006; Valadi et al., 2007), and oncogenic proteins (Koga 
et al., 2005; Al-Nedawi et al., 2008; Sanderson et al., 2008). 
5.5 Summary 
So far in the literature, exosomal cargo associated proteins and their importance in 
angiogenesis, inflammation, proteolysis regulators, membrane receptors, soluble factors, 
oncoproteins and tumor suppressors, lipids, nucleic acids are described briefly. Therefore, 
exosomes represent an integral part of both physiological regulation and disease 
pathogenesis, which may influence new therapeutic and diagnostic modalities. 
6. Membrane vesicles and antigen presentation 
As described earlier in this chapter, various cell types release exosomes, which contain a 
proteomic sampling from the cell of origin. Proteins within exosomes can be presented as 
www.intechopen.com
 The Application of Membrane Vesicles for Cancer Therapy 
 
35 
antigens to the immune system and, when derived from certain cell types, are capable of 
presenting antigens to immune cells directly. Antigen presentation by antigen presenting 
cells (APCs) requires several important steps to elicit an immune response: 1. the APC 
internalizes and processes the antigen, 2. the processed antigen is inserted into Major 
Histocompatibility Complex (MHC) molecules and displayed on the cell surface, 3. MHC 
molecules interact with T cell receptors to start a signaling cascade to activate the T cell (Kim 
et al., 2004). Dendritic cells are the primary APC type that stimulates T cells in vivo, which 
requires MHC molecules on the dendritic cell, as well as expression of co-stimulatory 
molecules that enhance T cell activation, such as CD40, CD80 and CD86 (Kim et al., 2004). 
Like many other cell types, dendritic cells release membrane vesicles, particularly exosomes, 
which help modulate the immune response (Chaput et al., 2006; Schorey & Bhatnagar, 2008; 
Thery et al., 2009). 
6.1 Antigen presentation by immune cell exosomes 
Antigen presenting cells, such as dendritic cells and B cells, release exosomes equipped with 
MHC class I and class II molecules that allow direct presentation of antigens to cytotoxic 
and helper T cells, respectively (Kim et al., 2004; Chaput et al., 2006). Antigens processed by 
APCs are loaded into MHC molecules and the MHC-antigen complex is released into the 
extracellular space within exosomes. These exosomes then travel throughout the body and 
induce an immune response by stimulating antigen-specific T cells. In addition to MHC 
molecules, APC exosomes express surface co-stimulatory molecules CD40, CD80 and CD86 
to enhance T cell activation (Raposo et al., 1996). The ability of exosomes to induce a T cell 
response is dependent on the expression of these molecules, as introduction of antibodies 
against CD40, CD80 and CD86 inhibit antigen presentation and T cell activation by APC 
exosomes. Additionally, the tetraspanin molecule CD54 (ICAM1) plays a crucial role in this 
process by enhancing exosome-T cell contact through its interaction with CD11a (LFA-1) on 
the T cell (Kim et al., 2004). This interaction allows MHC and co-stimulatory molecules to 
bind to their receptors on the T cells long enough to provide sufficient signaling. As 
observed with inhibition of the co-stimulatory molecules, antibody blockade of CD54 on 
exosomes dramatically reduces T cell activation by APC exosomes (Kim et al., 2004).  
6.2 Transfer of antigens by exosomes 
In addition to their ability to present processed antigens, exosomes can also transfer 
antigens from one cell to another. Exosomes containing cellular antigens are taken up by 
APCs, where the antigens are processed and inserted into MHC molecules for presentation 
(Obregon et al., 2006). This is a very important mechanism in disease states, where infected 
or malignant cells release exosomes into the bloodstream that can be processed and 
presented by APCs throughout the body to induce an immune response (Bhatnagar & 
Schorey, 2007). In cancer, TEXs are taken up by APCs and activate tumor-specific T cells 
(Andre et al., 2002a). In vitro studies have shown that when T cells are incubated with TEX in 
the presence of naïve dendritic cells, both helper and cytotoxic T cells are activated in an 
antigen-specific manner (Thery et al., 2009).  Additionally, in vivo vaccination studies 
comparing TEX and irradiated tumor cells showed a stronger immune response in animals 
vaccinated with TEXs. These studies have led to two clinical trials, which will be discussed 
in detail later. 
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6.3 Summary 
Antigen presentation to T cells is the first and most critical step in the adaptive immune 
response. The ability of exosomes to supply antigens to dendritic cells for presentation as 
well as present antigens directly via exosomal MHC molecules is an important mechanism 
for detection of infection and malignancy. Induction of anti-cancer responses via tumor-
released exosome antigens is likely a key mechanism in immune surveillance to prevent 
tumor progression. Whether this can be utilized in tumor immunotherapies is under 
investigation and could prove useful in combination therapies. 
7. Antigen-independent roles of membrane vesicles in immune responses 
Antigen presentation by exosomes is primarily an immunostimulatory process, however 
exosomes have many antigen-independent functions that can both stimulate and inhibit the 
immune system (Schorey & Bhatnagar, 2008; Thery et al., 2009). These roles are dependent 
on the type of cell the exosomes originate from and the molecules they express (Andre et al., 
2002a; Abusamra et al., 2005a; Xiang et al., 2009; Chalmin et al., 2010; Szajnik et al., 2010; 
Zhang et al., 2011). In this way exosomes are important for proper immune function and 
immune regulation, but can also be hijacked by malignant cells to prevent detection by the 
immune system. 
7.1 Immune cell exosomes induce immune responses 
Dendritic cell exosomes (DEXs) are vital for stimulation of the adaptive immune response 
by their presentation of antigen to T cells (Figure 6), but induction of the humoral immune 
response is as important a function (Chaput et al., 2006). DEXs have been shown to stimulate 
Natural Killer (NK) cell responses critical to the clearance of infection and malignancy 
(Viaud et al., 2009). This function is mediated by the expression of interleukin-15 receptor 
alpha (IL-15R┙) and Natural Killer Group 2D (NKG2D) ligands on dendritic cell exosomes. 
Interleukin-15 (IL-15) is a cytokine that stimulates NK cell activation and proliferation. 
Exosomal IL-15R┙ can bind IL-15 in the extracellular space and deliver it to NK cells by 
exosomal binding to NKG2D on the surface of the NK cells (Viaud et al., 2009). Delivery of 
IL-15 in this manner significantly increases NK cell responses in vitro and in mice injected 
with autologous DEXs (Thery et al., 2009; Viaud et al., 2009). Because of their critical 
importance to tumor clearance, NK cell stimulation by DEXs could provide therapeutic 
benefits by increasing NK cell numbers in cancer patients. 
7.2 Tumor cell exosomes and the immune response 
The role of TEX in the progression of cancer is multifaceted, as they can affect tumor 
growth, invasion and metastasis, and therapy resistance. In addition to influencing other 
malignant cells, TEXs have significant effects on the immune response, both positive and 
negative. 
7.2.1 Exosomes from heat-shocked tumor cells induce immune activation 
The release of exosomes from normal and malignant cells is increased by heat shock and 
stress, with amplified proportions of Hsps within the exosome (Schorey & Bhatnagar, 2008). 
Culture of dendritic cells with exosomes from heat-shocked tumors resulted in higher 
expression of CD40, CD80 and CD86 than in dendritic cells cultured with control immune 
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cell exosomes or non-heat shocked tumor exosomes (Chen et al., 2006c). Additionally, the 
dendritic cells treated with heat shocked TEXs exhibited increased production of pro-
inflammatory cytokines tumor necrosis factor alpha (TNF┙), IL-1┚, and IL-12 (Chen et al., 
2006c). This is thought to be mediated by the increased amount of Hsps in the heat-shocked 
TEXs, though the exact mechanism is still under investigation.  
 
 
Fig. 6. Dendritic cell-derived exosomes interact with T cells through MHC class I, II, 
tetraspanins such as CD9, CD63, CD81 and through co-stimulatory molecules such as CD86. 
7.2.2 Tumor cell exosomes inhibit natural killer cells via NKG2D 
NK cells kill cancer cells by release of granules and perforins (Figure 7). NK cell activity is 
often lost in cancer patients, resulting in a reduced ability of the immune system to eliminate 
malignant cells (Clayton et al., 2008; Viaud et al., 2009; Ahiru et al., 2010). The NK cell 
receptor NKG2D is important in regulation of NK cell function, with some ligands 
stimulating and others inhibiting cytotoxic function (Clayton et al., 2008). As discussed 
earlier, DEXs expressing activating NKG2D ligands can enhance NK cell function and 
promote tumor clearance (Viaud et al., 2009). Other NKG2D ligands, such as MHC class I-
related chain A (MICA) can reduce NK cell function. Tumor cells abuse this normal ligand 
by upregulating MICA on the cell surface as well as on TEXs (Ahiru et al., 2010). Ovarian 
cancer exosomes expressing high levels of MICA were shown to decrease NK cell function 
in vitro by reducing their NKG2D receptor expression and their responsiveness to activating 
NKG2D ligands (Ahiru et al., 2010). This reduction in NK cell function is highly detrimental 
to the anti-tumor response and is one of many mechanisms by which tumors escape 
immune detection (Thery et al., 2009). 
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Fig. 7. DEX and TEX play opposing roles with regard to immune cell activation and 
prohibition. 
7.2.3 Fas ligand expression on tumor cell exosomes induce immune cell apoptosis 
Cytotoxic immune cells like cytotoxic T cells express Fas Receptor (FasR; CD95) and Fas 
ligand (FasL; CD95L) that allow them to induce apoptosis in target cells. Several cancer 
types including colon and ovarian carcinoma and melanoma cells express FasL to induce 
death of the very immune cells that attempt to kill them (Koyama et al., 2001). This is a 
primary mechanism of tumor-immune escape that prevents the immune system from 
eliminating transformed cells, resulting in disease progression. To further prevent cytotoxic 
killing by T cells, TEXs have been found to express high levels of surface-bound FasL 
(Abusamra et al., 2005a). Release of FasL via exosomes allows the tumor to kill FasR-
expressing immune cells at distant sites, as well as in the tumor microenvironment, further 
preventing tumor clearance. Interestingly, although both helper and cytotoxic T cells 
express FasR, exosomes containing FasL preferentially induce apoptosis in cytotoxic T cells 
and not in helper T cells (Abusamra et al., 2005a). The mechanism behind this is not fully 
understood, but may be due to favored interactions between exosomes and cytotoxic T cells 
due to other exosomal surface molecules (Figure 7). 
7.2.4 Tumor exosomes induce suppressive immune cell phenotypes 
Immune suppression within the tumor microenvironment prevents cytotoxic attack and 
promotes tumor progression. Like FasL and NKG2D inhibition, increasing 
immunosuppressive cell types can reduce cytotoxic immune responses. Two primary 
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inhibitory cell types have been implicated in cancer progression: regulatory T cells (Tregs) 
(Szajnik et al., 2010) and myeloid derived suppressor cells (MDSCs) (Xiang et al., 2009). 
These cell types inhibit both helper and cytotoxic T cell responses and reduces their 
production of inflammatory cytokines like interferon gamma (IFN-┛). Large numbers of 
immune cells are found within the tumor microenvironment, but Tregs and MDSCs are far 
more prominent in cancer patients than in healthy patients, leading to the hypothesis that 
immune suppression can be induced by the tumors (Xiang et al., 2009; Szajnik et al., 2010). 
Tumor cells can directly induce regulatory populations by secreting transforming growth 
factor beta (TGF-┚), which promotes differentiation of naïve T cells and myeloid precursor 
cells into their respective suppressive phenotypes. A similar mechanism is utilized by 
tumors to induce Tregs and MDSCs within the tumor microenvironment and the periphery 
by secretion of TGF-┚ in exosomes (Xiang et al., 2009; Chalmin et al., 2010; Szajnik et al., 
2010). Ovarian carcinoma derived exosomes were found to induce CD4+CD25+Foxp3+ Tregs 
from CD4+CD25- naïve T cells in vitro (Szajnik et al., 2010). This was found to be dependent 
on the presence of TGF-┚ and IL-10 in the exosomes and was inhibited by addition of 
neutralizing antibodies to both cytokines. In a similar study, mouse bone marrow myeloid 
precursor cells were shown to take up TEXs, inducing their differentiation into CD11b+Gr-1+ 
myeloid derived suppressor cells. Exosomal expression of TGF-┚ and prostaglandin E2 
(PGE2) was shown to induce this differentiation, which was inhibited by antibody 
neutralization (Xiang et al., 2009). The suppressive function of existing MDSCs is also 
increased by TEXs. Interaction of Hsp72 on the exosome with Toll-like receptor 2 (TLR2) on 
the MDSC induces Stat3 signaling to induce their immunosuppressive functions (Chalmin et 
al., 2010). By increasing immunosuppressive cell types, TEXs can prevent attack by cytotoxic 
cells (Figure 7). 
7.3 Summary 
Exosomes can have important antigen-independent effects on immune cells that vary with 
the cell type they are derived from as well as the state of the cells upon release. DEXs and 
TEXs can stimulate immune responses, which could provide therapeutic benefits. In 
contrast, tumor derived exosomes from several cancer types have been shown to prevent 
cytotoxic attack on the tumor by FasL-induced T cell death, NKG2D ligand-mediated 
suppression of NK cells and through induction of immune suppressor cells like Tregs and 
MDSCs. How TEXs can be utilized or inhibited therapeutically remains to be seen, but 
currently is an active area of research. 
8. Immune responses induced by in vitro purified membrane vesicles in vivo 
Many studies described in the Sections 6 and 7 were performed using membrane vesicles 
and exosomes isolated and introduced to immune cell cultures in vitro. Before these findings 
can be utilized therapeutically, they must be confirmed in in vivo animal models. Results 
from these animal studies have demonstrated the importance of exosomes in immune 
modulation and are currently being implemented in clinical trials. 
8.1 Vaccination with tumor exosomes prevent tumor growth in mice 
Early studies in tumor vaccination utilized irradiation-killed tumor cells with limited 
success. With the discovery of TEXs, mouse vaccination studies with TEXs were shown to be 
more effective at generating tumor-specific T cell responses than irradiated tumor cells.  
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Additionally, vaccination of mice with exosomes containing ovalbumin resulted in delayed 
growth of ovalbumin-expressing tumors and induced pro-inflammatory Th1 T cell 
responses. As described in Section 7.2, exosomes isolated from heat-shocked cancer cells are 
more immunogenic in vitro. Using heat-shocked TEXs for immunization in mice showed 
similar immunogenicity, with 80% of mice remaining tumor free after challenge.  While 
these studies have provided the groundwork for cancer vaccines, the immunosuppressive 
functions of cancer exosomes have caused many to be skeptical of their use as vaccine. 
8.2 Dendritic cell exosomes containing tumor antigens induce anti-tumor immune 
responses 
The use of DEXs as artificial antigen presenting cells can elicit strong antigen-specific T cell 
responses (Kim et al., 2004). Mouse studies using DEXs pulsed with tumor peptides resulted 
in the activation of tumor-specific T cells, proliferation of NK cells and tumor regression 
(Kim et al., 2004; Chaput et al., 2006). Utilization of this technology with great success in 
murine studies has led to the development of several clinical trials using autologous DEXs 
as a treatment in cancer patients (Figure 8). 
8.2.1 Melanoma phase I trial 
A Phase I trial using dendritic cell exosomes to induce tumor regression was evaluated in 15 
patients with metastatic melanoma (Escudier et al., 2005). Autologous monocytes were 
isolated from patients by leukapheresis and differentiated in vitro to dendritic cells.  These 
dendritic cells were cultured, exosomes isolated from the culture medium and pulsed with 
peptides from the tumor antigen MAGE3 (Escudier et al., 2005). Patients received escalating 
doses of cryopreserved exosomes and their tumor progression and immune responses 
monitored. All 15 patients completed therapy but only 1 had specific T cell responses. Skin 
and lymph node mass reduction was observed in 5 of 15 patients and 7 of 15 patients 
showed increased NK cell activity (Escudier et al., 2005; Thery et al., 2009). 
 
 
Fig. 8. Dendritic cell exosomes can be harvested and used in immunotherapy. 
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8.2.2 Non-small cell lung cancer phase I and II trials  
A similar trial to the melanoma study was performed in Stage III and IV non-small cell lung 
cancer (NSCLC) (Morse et al., 2005). Of the 13 patients enlisted in the trial, 9 finished the 
treatments and no toxicity was observed. Immune responses to MAGE3 was observed in 3 
of 9 patients, with MAGE3-specific T cells only detected in 1 patient and while an increase in 
Treg cells was observed in 2 patients (Morse et al., 2005). This trial concluded that dendritic 
cell exosomes are safe for use therapeutically, but that better responses may result from 
including Treg inhibitors in the treatment. A Phase II trial has begun adding IL-15R and 
NKG2D to the exosomes as well as Treg inhibitor therapy in NSCLC patients whose disease 
has been stabilized by chemotherapy (Thery et al., 2009). 
8.3 Summary 
The use of exosomes as a cancer therapeutic has been demonstrated to be effective in murine 
studies and safe by Phase I clinical trials. Although some benefit was seen in patient trials, 
making these exosomal therapies more effective will likely require combination 
immunotherapies, chemotherapies and radiation. The use of exosomes to induce anti-cancer 
responses presents an exciting new field in cancer immunotherapy. 
9. Membrane vesicles as therapeutic agents 
Secreted microvesicles, known as exosomes, provide a form of cell to cell signaling in which 
the recipient cell can be modified by the contents of the delivered exosomes. The contents 
(cytosolic proteins, lipids, siRNA, miRNA, DNA, etc) (Tan et al., 2010; Khan et al., 2011) are 
protected and stably delivered unlike those secreted into the extracellular matrix (Pap et al., 
2010); thus securing the bioactivity of the delivered contents. Exosomes could be an 
attractive tool as an immunotherapeutic as they maintain much of the anti-tumor activity of 
a dendritic cell with the advantage of a cell free vehicle. Understanding that exosomes are 
involved in many levels of tumorigenesis, and potential strategies against this form of 
cellular communication has led to the creation of potential therapeutics against exosomes. 
TEXs are a protective measure for tumor cells that aids in survival, growth, invasion, 
metastasis, and evasion of the immune system (Clayton et al., 2007; Valenti et al., 2007; 
Anderson et al., 2010; Khan et al., 2011). Taxol and vinca alkaloids are well known 
chemotherapeutic agents, but they also limit exosome release via the microtubule formation. 
Exosome formation has also been shown to be blocked by decreasing acidity of the 
microcellular environment (Iero et al., 2008; Pap et al., 2010). Prevention of exosome 
formation involves a broad variety of proteins and is essential for life in all cells. Therefore 
any inhibition of exosomes within the body could lead to unwarranted side effects (Pap et 
al., 2010). It was thought that inhibition or treatment focused against TEXs and its ability to 
aid tumor cells could bear significant benefit to patients, but that was overshadowed by the 
realization that exosomes could potentially be employed as biomarkers and diagnostic tools 
of malignancy in blood (Anderson et al., 2010) and urine (Nilsson et al., 2009). One such 
study analyzed the correlation between serum PSA and urinary-exosomes, but none was 
observed. However, the data suggests that healthy donor urinary-exosomes were negative 
for PSA, PSMA, and 5T4 (Mitchell et al., 2009). 
Realizing that exosomes are secreted/released by a wide variety of cell types (Skokos et al., 
2001; Wolfers et al., 2001; Chaput et al., 2004b; Tan et al., 2010; Khan et al., 2011) including 
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immune cells and tumor cells, many studies set out to manipulate exosomes for cancer 
therapy, specifically immunotherapy. Ever since B lymphocytes were described to contain 
MHC class II molecules and stimulate CD4+ T cells (Raposo et al., 1996), studies have 
suggested exosomes may have an immunogenic role. Currently, DEXs from pulsed 
dendritic cells are under investigation for their ability to enhance and prime the immune 
system against tumor cells. Dendritic cells activate T cell responses through direct dendritic 
to T cell contacts. However, exosomes secreted by dendritic cells are also able to stimulate T 
cells (Zitvogel et al., 1998). 
9.1 Anti-cancer therapy 
The importance of exosomes in cell to cell communication can be seen in their antigen 
presenting ability. Seminal work during the late 1990’s showed DC’s pulsed/loaded with 
cancer antigens or tumor peptides could yield DEXs which elicited better immune responses 
towards tumor cells (Zitvogel et al., 1998; Wolfers et al., 2001; Couzin, 2005; Chaput et al., 
2006; Tan et al., 2010). The immune response was due to DEXs displaying the appropriate 
MHC class I molecules and tumor peptides. In fact, DC can be pulsed with both MHC class I 
and II, therefore effectively priming T cells against tumors (Thery et al., 2002; Andre et al., 
2004; Chaput et al., 2004a; Mignot et al., 2006) as well as stimulating the activation and 
proliferation of NK cells (Clayton et al., 2007; Viaud et al., 2009). Current literature suggests 
that MHC class I and II containing exosomes are potential cell-free cancer vaccines (Zitvogel 
et al., 1998; Andre et al., 2004; Chaput et al., 2004a; Tan et al., 2010). Unlike current clinical 
cancer vaccines, exosomes are not technically vaccines as they are preventative and not 
therapeutic. The prophylactic vaccines are only effective against oncogenic viruses and do 
not treat the cancer directly, not to mention too expensive for the average patient (Tan et al., 
2010). Treatment of tumors with DEXs has had beneficial results such as initiation of 
immune response (Couzin, 2005), tumor growth suppression (Zitvogel et al., 1998), tumor 
shrinking (Viaud et al., 2009), and tumor rejection (Wolfers et al., 2001; Mignot et al., 2006). 
Exosomes are a better alternative than DC in terms of therapy because its composition can 
be identified, measured, is stable for storage, and has predictable behavior after 
administration (Thery et al., 2002; Chaput et al., 2004b).  
The utilization of exosomes for cancer immunotherapy is a very new but very rapidly 
growing field. Most studies were conducted in vitro, but it is still unclear how oncologists 
will be able to translate the literature’s data into the realm that will be most beneficial for the 
patient. One such complication is how the DEXs will be collected and implemented for 
patient treatment, and will the collected DEXs be sufficient enough? One potential strategy 
involves isolating DEXs through filtration of the patient’s blood which will then be returned 
and employed to stimulate the immune system (Couzin, 2005). This would certainly allow 
for personalized therapy, but the question still remains: would there be enough DEXs and if 
not could adjuvant augmentation increase their numbers. Although the mode of exosome 
action in vivo is not clear yet, DEXs are a very interesting and potential substitute for 
dendritic cells in tumor vaccination therapy. 
10. Conclusion 
Various secreted extracellular vesicles have been found in blood, saliva, breast milk, 
bronchoalveolar lavage fluid, urine and amniotic fluid. Cellular uptake mechanisms have 
been shown to range from ligand/receptor interactions, integrin/cell adhesion molecule 
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attachment and fusion, or through transcytosis. Physiologically, these extracellular vesicles 
have been shown to play a role in inter-cellular communication, disposal of defective or 
weakened proteins, formation of morphogen gradients for tissue patterning during 
development and for antigen presentation to T cells. Pathologically, these vesicles have been 
shown to aid in the transmission of viruses, prions, -amyloid in Alzheimer’s disease, and 
specifically to this chapter, tumor pathogenesis. Although additional investigation is still 
needed to fully exploit these extracellular vesicles for therapy, there is increasing evidence 
that in better understanding them and the molecules that they transport, determinations of 
diagnosis and prognosis and the prediction of response to treatment may be possible. 
However, it is also the hope that these vesicles may also act at therapeutic targets and 
perhaps even replacement therapies. 
Conventional treatments for cancer include the use of chemotherapeutic drugs, radiation 
therapy and interventional surgery if the tumors are operable. Recent data suggests that the 
application of dendritic cell-derived, tumor cell-derived and even ascitic cell-derived 
exosomes could be developed as novel treatments for cancer. In fact, is has already been 
established that exosomes can be safely administered to patients, though the number of 
patients in these trials have been small and thus argue for larger studies. Furthermore, the 
goal of exosome therapy is to increase the biological magnitude of the immune response and 
as such exosomal immunotherapy is heavily reliant on the immune system. It will therefore 
be important to address issues such as patient immunosuppression due to therapeutic 
treatment, as the efficacy of the immunotherapy will be reliant upon the capability of the 
immune system. In order to increase the biological magnitude of the immune response 
researchers are artificially coating and engineering exosomes with tumor antigens to make 
them more recognizable to the immune system. The affects of heat shocking exosomes is 
also being investigated as heat shocked tumor exosomes are more effective than those not 
receiving heat treatment. Heating of the exosome confers a greater immunogenicity and 
thus elicits a greater immune response. Another possible application for exosomes is in 
vaccine delivery as exosome-producing cells could be engineered to produce a miRNA or 
specific genetic component or toxin that could be loaded into a exosome with the proper 
surface molecules for a cell specific uptake and response. Finally, the application of 
exosomes as immunotherapeutics represents a new chapter in cancer treatment 
development. However, much more research must go into elucidation of mechanism and 
targeting in order to improve potency. 
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